Biofil Chemicals & Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended December 31, 2025.
BIOFILCHEM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Biofil Chemicals & Pharmaceuticals reported its Q3 FY26 results on February 13, 2026, showing a dramatic sequential revenue collapse to just ₹85.63 lakhs from ₹1,354.08 lakhs in Q2 FY26, as the company's factory underwent renovation and upgradation for Schedule M (Drugs & Cosmetics Rules) compliance, partially disrupting manufacturing. For the nine months ended December 2025, revenue from operations declined about 17% year-on-year to ₹2,082.96 lakhs (vs ₹2,505.12 lakhs in 9M FY25). Despite weak operations, 9M profit after tax surged to ₹257.37 lakhs from ₹35.81 lakhs, almost entirely driven by a non-operating 'Other Unallocable Income' of about ₹291 lakhs. The statutory auditor (Maheshwari & Gupta) issued an unmodified review opinion. The Pharma segment posted a loss of ₹10.45 lakhs in Q3, while the Chemicals division remained profitable at ₹16.73 lakhs. Q3 EPS stood at ₹0.05.
The headline PAT jump looks impressive but is misleading since it is propped up by a one-time non-operating gain rather than core business performance. Real operations are under pressure with revenue sharply down and the Pharma segment loss-making in Q3, though the factory upgrade is a necessary step. Shareholders should not read the 9M profit growth as a sign of sustainable business momentum; the negative reserves (₹-125.42 lakhs as of March 2025) are also a lingering concern.